According to Ardelyx's latest financial reports the company's current EPS (TTM) is -$0.12. In 2022 the company made an earnings per share (EPS) of -$0.48 an increase over its 2021 EPS that were of -$1.52.
Year | EPS | Change |
---|---|---|
2023 (TTM) | -$0.12 | -75% |
2022 | -$0.48 | -68.42% |
2021 | -$1.52 | 44.76% |
2020 | -$1.05 | -28.57% |
2019 | -$1.47 | -9.26% |
2018 | -$1.62 | 19.12% |
2017 | -$1.36 | -51.94% |
2016 | -$2.83 | 154.95% |
2015 | -$1.11 | 524.75% |
2014 | -$0.18 | -63.88% |
2013 | -$0.49 |
Company | EPS | EPS differencediff. | Country |
---|---|---|---|
Abbott Laboratories ABT | $2.97 | -2,576.83% | ๐บ๐ธ USA |
Amgen AMGN | $14.15 | -11,891.67% | ๐บ๐ธ USA |
Sanofi SNY | $3.18 | -2,750.21% | ๐ซ๐ท France |
AstraZeneca AZN | $1.98 | -1,754.17% | ๐ฌ๐ง UK |
OPKO Health
OPK | -$0.27 | 125.00% | ๐บ๐ธ USA |